Antipsychotic News and Research

RSS

Antipsychotics are medicines used to treat the symptoms of mental disorders such as schizophrenia, depression, bipolar disorder (sometimes called manic-depressive illness), anxiety disorders, and attention deficit-hyperactivity disorder (ADHD). Sometimes medications are used with other treatments such as psychotherapy.

Risperdal Consta can reduce risk of hospitalisation in patients with schizophrenia

New data from an independent prospective study presented last week at the 19th European Congress of Psychiatry shows treatment with Risperdal Consta is associated with a lower risk of hospitalisation in patients with schizophrenia compared to treatment with other antipsychotics over a 12-month period.

5 Apr 2011

Non-generic drugs increase Medicaid costs

A new study by the American Enterprise Institute found that using brand-name drugs instead of generics may have added as much as $329 million in extra spending in 2009.

30 Mar 2011

Atypical antipsychotics is a safe mental health medication for nursing home residents

Conventional antipsychotics, antidepressants and benzodiazepines often administered to nursing home residents are no safer than atypical antipsychotics and may carry increased risks, according to an article in CMAJ.

29 Mar 2011

AssureRx closes $11 million Series B financing

AssureRx Health, Inc. today announced the closing of an $11 million Series B financing. The personalized medicine company, which provides clinically-relevant information to help physicians select the right drug and the right dose for individual neuropsychiatric patients, will use the funds to expand direct sales and marketing for its first product, GeneSightRx®, and for second generation product development activities.

25 Mar 2011

Report highlights common problems in Nordic mental health care reforms

In Denmark, Norway, Finland and Sweden reforms within psychiatry have transformed inpatient care to the point where it has increasingly been replaced by outpatient care.

23 Mar 2011

Physical ill-health reduces life expectancy of people with severe mental illness

Physical ill-health is rife among the severely mentally ill in Britain, according to new research published today by the University of East Anglia (UEA).

21 Mar 2011

Researchers discover a type of 'cellular bilingualism' in brain

A team of researchers from the University of Montreal and McGill University have discovered a type of "cellular bilingualism" - a phenomenon that allows a single neuron to use two different methods of communication to exchange information.

18 Mar 2011

Transcept initiates enrollment in TO-2061 Phase 2 study for treatment resistant obsessive compulsive disorder

Transcept Pharmaceuticals, Inc. today announced the first patient has been enrolled in a Phase 2 clinical study to evaluate TO-2061 as an adjunctive treatment for obsessive compulsive disorder (OCD) in patients who have responded inadequately to currently approved treatments. OCD affects 1 to 2 percent of the United States adult population and can significantly impair the lives of patients and their families.

14 Mar 2011

EDT receives European approval for XEPLION injection to treat schizophrenia

Elan Drug Technologies, the drug delivery unit of Elan Corporation, plc, today announced that the first injectable product using EDT's NanoCrystal technology has been approved by the European Commission.

9 Mar 2011

Preliminary top-line results from cariprazine 8-week Phase II trial against major depressive disorder

Forest Laboratories, Inc. and Gedeon Richter Plc. today announced preliminary top-line results from an 8-week Phase II clinical trial of the novel, investigational antipsychotic agent cariprazine as adjunctive therapy in major depressive disorder.

28 Feb 2011

FDA warning leads to decrease in use of atypical antipsychotics for treatment of dementia

A warning issued by the Food and Drug Administration regarding the use of atypical antipsychotics for the treatment of dementia was associated with a significant decline in the use of these medications for treating dementia symptoms in elderly patients, according to a report in the February issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

8 Feb 2011

Schizophrenia patients who consume antipsychotics appear to lose small amount of brain tissue

Patients with schizophrenia who take antipsychotic medications appear to lose a small but measurable amount of brain tissue over time, according to a report in the February issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

8 Feb 2011

Study reports significant decline in second-generation medication use for dementia

As loved ones with dementia disappear into symptoms of aggression, agitation or delusions, families are left with few good medical solutions. A new generation of antipsychotic medications gained popularly in the 1990s because they avoided side effects such as Parkinson's syndrome associated with conventional antipsychotic medications used to treat dementia.

8 Feb 2011

HMORN, iSAEC collaborate to enroll subjects in SAE research project using EMR database

The International Serious Adverse Events Consortium announced today a new collaboration with the HMO Research Network to enroll subjects in research to identify genetic markers that may help predict risk associated with a range of serious drug-related adverse events.

3 Feb 2011

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Johnson & Johnson today announced sales of $15.6 billion for the fourth quarter of 2010, a decrease of 5.5% as compared to the fourth quarter of 2009. Operational sales declined 5.1% and the negative impact of currency was 0.4%. Domestic sales declined 8.1%, while international sales declined 3.1%, reflecting an operational decline of 2.3% and a negative currency impact of 0.8%.

25 Jan 2011

MGH Bipolar CHOICE trial to evaluate effectiveness of new medications compared to lithium

The Massachusetts General Hospital (MGH) Bipolar Clinic and Research Program with the Bipolar Trials Network is launching Bipolar CHOICE, a 10-site nationwide trial evaluating the real-world advantages and disadvantages of quetiapine, a widely prescribed second generation antipsychotic mood stabilizing medication, compared to lithium, the gold standard mood stabilizer, for the treatment of outpatients with bipolar disorder.

21 Jan 2011

Antipsychotic News and Research

Risperdal Consta can reduce risk of hospitalisation in patients with schizophrenia

Non-generic drugs increase Medicaid costs

Atypical antipsychotics is a safe mental health medication for nursing home residents

AssureRx closes $11 million Series B financing

Report highlights common problems in Nordic mental health care reforms

Physical ill-health reduces life expectancy of people with severe mental illness

Researchers discover a type of 'cellular bilingualism' in brain

Transcept initiates enrollment in TO-2061 Phase 2 study for treatment resistant obsessive compulsive disorder

EDT receives European approval for XEPLION injection to treat schizophrenia

Preliminary top-line results from cariprazine 8-week Phase II trial against major depressive disorder

FDA warning leads to decrease in use of atypical antipsychotics for treatment of dementia

Schizophrenia patients who consume antipsychotics appear to lose small amount of brain tissue

Study reports significant decline in second-generation medication use for dementia

HMORN, iSAEC collaborate to enroll subjects in SAE research project using EMR database

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

MGH Bipolar CHOICE trial to evaluate effectiveness of new medications compared to lithium

Positive top-line results from TC-5619 Phase 2 trial in patients with schizophrenia

UH, Case Western University commence clinical trial for bipolar disorder

CAMH scientists receive NARSAD's Young Investigator grant awards for brain and behavior research

Stigma remains over Major Depressive Disorder

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News